文献速递中毒与环境急症消化、代谢与肾脏急症

体外分析:N-乙酰半胱氨酸对国际标准化比值(INR)检测的干扰

In vitro analysis of n-acetylcysteine (NAC) interference with the international normalized ratio (INR).
PubMed 文献 · Clin Toxicol (Phila) · 2021-09-22
一句话结论体外治疗浓度NAC可使INR检测值轻度升高,但幅度很小、临床意义有限;超治疗浓度时INR显著非线性升高,但临床少见。

该研究为体外实验,采集11名健康志愿者血样,加入不同浓度NAC(0、35、70、200、550、1000、2000、4000 mcg/mL),在Siemens CS-2500和Stago SN1114559两台血凝仪上测定PT和INR。治疗浓度(基线、35、70、200、550 µg/mL)间INR存在显著差异(Siemens p=.0008,Stago p<.0001),但仅个别浓度与基线比较有统计学差异,最大INR升高为1例受试者在550 µg/mL时从1.07升至1.32。超治疗浓度时INR呈显著非线性升高(两台仪器均p<.0001),所有浓度与基线比较均有显著差异(校正p<.05)。作者结论认为治疗浓度下NAC对INR的影响临床意义很小,超治疗浓度虽影响显著但临床罕见。

要点

  • 体外治疗浓度NAC可使INR轻度升高:Siemens分析仪550 µg/mL时INR 1.07 vs 基线1.22(p=.02);Stago分析仪200 µg/mL和550 µg/mL时INR 1.00 vs 1.07和1.19(校正p=.02和p=.03)。
  • 最大个体INR升高为1例受试者在550 µg/mL浓度时从基线1.07升至1.32。
  • 治疗浓度下NAC对INR的影响幅度小,作者认为临床意义有限。
  • 超治疗浓度(1000、2000、4000 mcg/mL)导致INR显著非线性升高(Siemens p<.0001,Stago p<.0001),所有浓度与基线比较均有显著差异(校正p<.05)。
  • 超治疗浓度INR结果的临床实用性受限于这些浓度在临床中很少被检测到。

适用人群与场景

  • 体外实验,血样来自11名健康志愿者:8名男性、3名女性,中位年龄30岁(范围25-58岁)。

研究设计与关键结果

  • 研究类型为体外实验,样本量为11名健康志愿者的血样,未报告中心数;将血样加入不同浓度NAC(0、35、70、200、550、1000、2000、4000 mcg/mL)后在Siemens CS-2500和Stago SN1114559两台血凝仪上测定PT和INR。
  • 基线INR中位数(IQR):Siemens为1.09(1.05,1.16),Stago为1.03(0.99,1.11)。
  • 治疗浓度(基线、35、70、200、550 µg/mL)间INR存在显著差异:Siemens p=.0008,Stago p<.0001。
  • Siemens分析仪仅550 µg/mL浓度与基线单独比较有显著差异:INR 1.07 vs 1.22(p=.02)。
  • Stago分析仪200 µg/mL和550 µg/mL浓度与基线比较有显著差异:INR 1.00 vs 1.07(校正p=.02)和1.00 vs 1.19(校正p=.03)。
  • 最大INR升高为1例受试者在550 µg/mL浓度时从基线1.07升至1.32。
  • 超治疗浓度(1000、2000、4000 mcg/mL)导致INR显著非线性升高(Siemens p<.0001,Stago p<.0001),所有浓度与基线比较均有显著差异(校正p<.05)。

证据类型、等级与局限

  • 证据类型:体外实验。
  • 作者结论:治疗浓度下NAC对INR的影响临床意义很小;超治疗浓度虽影响显著,但临床实用性受限于这些浓度很少被检测到。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 体外治疗浓度NAC可使INR检测值轻度升高,但作者认为该变化临床意义有限。
  • 超治疗浓度NAC可显著影响INR,但作者指出这些浓度在临床中很少被检测到。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Previous literature suggests a laboratory interference of n-acetylcysteine (NAC) with prothrombin time (PT) and the international normalized ratio (INR). Early publications focused on this interaction in the setting of an acetaminophen overdose and evaluated the INR of patients receiving intravenous NAC. However, there is limited literature describing the concentration-effect relationship of NAC to INR measurement in the absence of acetaminophen-induced hepatotoxicity at therapeutic NAC concentrations. The purpose of the study is to quantify the degree of interference of NAC on INR values at therapeutic concentrations correlating to each infusion of the regimen (ex. bag 1: 550 mcg/mL, bag 2: 200 mcg/mL, bag 3: 35 mcg/mL, double bag 3: 70 mcg/mL) and at supratherapeutic concentrations in vitro.

METHODS: Blood samples were obtained from study volunteers. Each blood sample was transferred into vials containing 0.3 mL buffered sodium citrate 3.2% and spiked with various concentrations of NAC for final concentrations of 0, 35, 70, 200, 550, 1000, 2000, and 4000 mcg/mL. The samples were centrifuged and tested to determine PT and INR on two separate machines: Siemens CS-2500 and Stago SN1114559. We would require a sample size of 6 to achieve a power of 80% and a level of significance of 1.7% (two-sided). Differences between INRs at varying concentrations were determined by Friedman's test. For multiple comparisons, post hoc analysis was performed using Wilcoxon signed-rank test with Bonferroni adjustment. Analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC).

RESULTS: Participants included 11 healthy subjects: 8 males, 3 females, median age 30 years (range 25 - 58). Median and interquartile ranges (IQR) INR for the baseline samples were 1.09 (IQR 1.05, 1.16) for Siemens and 1.03 (IQR 0.99, 1.11) for Stago analyzers. There was a significant difference in INR between the therapeutic concentrations (baseline, 35, 70,200, or 550 µg/mL) (Siemens p = .0008, Stago p < .0001). The 550 µg/mL concentration with the Siemens analyzer was the only one compared separately and found to be significantly greater than the baseline (1.07 vs 1.22, p = .02). For the Stago analyzer the 200 µg/mL and 500 µg/mL were compared and found to be significantly different from baseline (1.00 vs 1.07 and 1.19, adjusted p = .02 and p = .03, respectively). The largest INR increase seen was in one subject from a baseline of 1.07-1.32 with the 550 µg/mL concentration. Increases in concentrations to supratherapeutic levels resulted in a statistically significant non-linear increase in INR for all concentrations (Siemens p < .0001, Stago p < .0001). All of these concentrations were found to be significantly different from baseline (all adjusted p < .05).

CONCLUSION: Although it was found that at therapeutic concentrations the in vitro presence of NAC affects INR measurements on two different machines, the change is of little clinical relevance. Supratherapeutic concentrations of NAC affect INR significantly, but the clinical utility of those results is limited by the rarity of those concentrations being measured.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Minhaj FS, Leonard JB, Seung H, et al. In vitro analysis of n-acetylcysteine (NAC) interference with the international normalized ratio (INR). Clin Toxicol (Phila). 2021. PMID: 34549665. doi:10.1080/15563650.2021.1979232

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。